Feb 10 2014
Mallinckrodt (NYSE: MNK) today announced the commercial launch of PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.
"We are excited to make PENNSAID 2% available for patients who suffer from pain associated with osteoarthritis of the knee," said Hugh O'Neill, Senior Vice President and President, U.S. Specialty Pharmaceuticals, Mallinckrodt. "This launch is the result of our continued commitment as a company to bringing additional NSAID treatment options to the market."
PENNSAID 2% was approved by the U.S. Food and Drug Administration January 16, 2014. U.S. sales and marketing rights for PENNSAID 2% are licensed to Mallinckrodt by Nuvo Research Inc. (TSX:NRI).
Posted in: Medical Condition News | Pharmaceutical News
Tags: Abdominal Pain, Anti-Inflammatory, Aspirin, Asthma, Blood, Blood Pressure, Cardiovascular Disease, Clinical Trial, Coronary Artery Bypass Graft, Dermatitis, Diarrhea, Drugs, Dyspepsia, Erythema, Exercise, Flatulence, Heart Failure, Hypersensitivity, Knee, Medical Imaging, Nausea, Osteoarthritis, Pain, Pharmaceuticals, Placebo, Pruritus, Research, Stroke, Urinary Tract Infection, Urticaria
